H.R. 1492 · 119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Introduced on Feb 21, 2025 by Gregory F. Murphy (R-NC-3). 68 cosponsors, 4 of them from another party. Latest action (Feb 21, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Stage
Introduced
Introduced
Feb 21, 2025
Cosponsors
68
4 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Subjects

  • Health care costs and insurance
  • Medicare
  • Prescription drugs

Summary

By the Congressional Research Service (Introduced in House, Feb 21, 2025). Public domain.

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.

The bill's changes apply retroactively.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Gregory F. MurphyR-NC-3Sponsor

Democrats · 4

Republicans · 64

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Feb 21, 2025Introduced in House
  2. Feb 21, 2025Introduced in House
  3. Feb 21, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Feb 21, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA42 reports
    $57.5M reported (all issues)
  2. NOVARTIS CORPORATION15 reports
    $13.1M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  3. GENENTECH INC.10 reports
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  4. MERCK & CO., INC.10 reports
    $7.6M reported (all issues)Federal contractor: MERCK SHARP & DOHME LLC$445.3K in contracts, FY2026AI match · 100%
  5. PFIZER INC.10 reports
    $8M reported (all issues)Federal contractor: PFIZER INCAI match · 100%
  6. Pharmaceutical Research and Manufacturers of America (PhRMA)10 reports
    $370K reported (all issues)
  7. AMGEN INC.9 reports
    $18.3M reported (all issues)Federal contractor: AMGEN INC.AI match · 99%
  8. EMD SERONO, INC.9 reports
    $4.7M reported (all issues)
  9. GILEAD SCIENCES, INC.8 reports
    Federal contractor: GILEAD SCIENCES INCAI match · 100%
  10. Sanofi U.S. Services, Inc.8 reports
    $460K reported (all issues)
  11. Pharmaceutical Industry Labor-Management Association7 reports
    $350K reported (all issues)
  12. SOLENO THERAPEUTICS, INC.7 reports
    $370K reported (all issues)
  13. Amgen USA, Inc.6 reports
    $360K reported (all issues)Federal contractor: AMGEN USA INC$126M in contracts, FY2026AI match · 100%
  14. BIOGEN INC.6 reports
    $5.7M reported (all issues)
  15. BIOTECHNOLOGY INNOVATION ORGANIZATION6 reports
    $9.6M reported (all issues)
  16. BOEHRINGER INGELHEIM USA CORPORATION6 reports
    $5.5M reported (all issues)Federal contractor: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC$3.5M in contracts, FY2026AI match · 99%
  17. Bayer Corporation (consolidated report)6 reports
    $13.1M reported (all issues)
  18. GSK (fka GLAXOSMITHKLINE INC.)6 reports
    $7.4M reported (all issues)
  19. HealthCare Institute of New Jersey6 reports
    $283.8K reported (all issues)
  20. JOHNSON & JOHNSON SERVICES, INC.6 reports
    $13.3M reported (all issues)
  21. LUNDBECK LLC6 reports
    $930K reported (all issues)Federal contractor: LUNDBECK LLCAI match · 99%
  22. NEUROCRINE BIOSCIENCES, INC.6 reports
    $5.5M reported (all issues)Federal contractor: NEUROCRINE BIOSCIENCES, INC.AI match · 100%
  23. NOVO NORDISK INC.6 reports
  24. PTC THERAPEUTICS, INC.6 reports
    $1.2M reported (all issues)
  25. Public Citizen6 reports
    $548.1K reported (all issues)
  26. ACADIA PHARMACEUTICALS5 reports
    $3.1M reported (all issues)
  27. BRISTOL-MYERS SQUIBB COMPANY5 reports
    $13.7M reported (all issues)Federal contractor: BRISTOL-MYERS SQUIBB COMPANY$8.8M in contracts, FY2026AI match · 100%
  28. OTSUKA AMERICA PHARMACEUTICAL, INC4 reports
    $3.7M reported (all issues)Federal contractor: OTSUKA AMERICA PHARMACEUTICAL INCAI match · 100%
  29. THE ALS ASSOCIATION4 reports
    $120K reported (all issues)
  30. AARP3 reports
    $14.2M reported (all issues)
  31. CHRONIC CARE POLICY ALLIANCE3 reports
    $40K reported (all issues)
  32. Genentech USA, Inc.3 reports
    $150K reported (all issues)Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  33. IONIS PHARMACEUTICALS, INC.3 reports
    $370K reported (all issues)
  34. National Alliance on Mental Illness3 reports
    $40K reported (all issues)
  35. Personalized Medicine Coalition3 reports
    $133K reported (all issues)
  36. CALIFORNIA LIFE SCIENCES2 reports
  37. HARMONY BIOSCIENCES, LLC2 reports
    $360K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  38. Healthcare Leadership Council2 reports
    $370K reported (all issues)
  39. INTRA-CELLULAR THERAPIES, INC.2 reports
    $80K reported (all issues)
  40. PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2 reports
    $6.4M reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 5, 2026 · loaded Oct 5, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.